



For maximal transparency, ERN RARE-LIVER asks its network governance to provide information on their interests outside of ERN RARE-LIVER in **the past 3 years** that could influence how they make decisions when leading activities of the network. Relevant activities to be reported are research grants > 5000€, as well as lecture fees and travel grants, fees for consulting and advisory boards, as well as fees for patient association activities each > 1000€. Additionally, other interests as investments, stock and patents are disclosed.

A–E

Annalisa Berzigotti received lecture fees and travel grants from GE Healthcare; fees for consulting and advisory boards from Boehringer Ingelheim.

Nora Cazzagon received research grants from Orphalan; lecture fees and travel grants from Ipsen and Orphalan; fees for consulting and advisory boards from Ipsen, Gilead, Advanz, Orphalan, GSK and Albireo.

Elena Corradini reports no conflicts of interest.

Juan Carlos Garcia-Pagan received research grants from Mallinckrodt, COOK and GORE; lecture fees and travel grants from COOK and GORE; fees for consulting and advisory boards from AstraZeneca.

F–K

Lorenz Grossar reports no conflicts of interest.

L–P

Angela Leburgue reports no conflicts of interest.

Ansgar W. Lohse received lecture fees and travel grants from Falk Foundation.

Aurélie Plessier reports no conflicts of interest.

Antonello Pietrangelo reports no conflicts of interest.

Q–Z

Christoph Schramm received research grants from Roche; lecture fees and travel grants from Falk Foundation; fees for consulting and advisory boards from Pliant Therapeutics, Chemomab, Agomab.

Marcial Sebode received lecture fees and travel grants from Dr Falk GmbH.